|
CN107827837A
|
|
Phosphate receptor modulators compound of sphingol 1 and preparation method and application
|
|
CN107663217A
|
|
Tenofovir Chinese mugwort draws phenol amine crystalline compounds and preparation method thereof
|
|
CN107445948A
|
|
A kind of newtype drug midbody compound and its production and use
|
|
CN107226790A
|
|
A kind of preparation method and midbody compound of high-purity tafluprost and its similar compound
|
|
CN106589039A
|
|
A method for preparing obeticholic acid and related compound
|
|
CN106138043A
|
|
A kind of Candesartan compound of double action
|
|
CN106146471A
|
|
A kind of Irbesartan compound of double action
|
|
CN106138057A
|
|
A kind of Fimasartan compound of double action
|
|
CN106138041A
|
|
A kind of Losartan compound of double action
|
|
CN106146472A
|
|
A kind of A Lishatan compound of double action
|
|
CN106138042A
|
|
A kind of Olmesartan compound of double action
|
|
CN105985329A
|
|
Novel posaconazole compound preparation method
|
|
CN105985346A
|
|
Preparation method of novel ticagrelor compound and intermediate compound of ticagrelor compound
|
|
CN105985393A
|
|
Method for preparing high-purity telbivudine compound
|
|
CN105985309A
|
|
High-purity lubiprostone compound and preparation method thereof
|
|
CN105985388A
|
|
Fondaparinux sodium impurity compound, preparation method therefor and application of Fondaparinux sodium impurity compound
|
|
CN105985387A
|
|
Fondaparinux sodium impurity compound, preparation method therefor and use of Fondaparinux sodium impurity compound
|
|
CN105218520A
|
|
A kind of preparation method of esomeprazole magnesium crystallization dihydrate
|
|
CN105272867A
|
|
Acetyl-L-carnitine crystalline compound and preparation method thereof
|
|
CN103467445A
|
|
Preparation method of alogliptin benzoate
|
